letibotulinumtoxina 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5810 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • letibotulinumtoxina
  • letibotulinumtoxina-wlbg
  • letybo
LetibotulinumtoxinA-wlbg is an acetylcholine release inhibitor and neuromuscular blocking agent. LetibotulinumtoxinA-wlbg blocks peripheral cholinergic transmission at the neuromuscular junction by inhibiting acetylcholine release from presynaptic nerve terminals.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 29, 2024 FDA Hugel Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug effect less than expected 416.11 153.51 54 106 6084 90622203
Therapy non-responder 272.19 153.51 58 102 136646 90491641

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug effect less than expected 236.04 127.69 31 70 7289 110581909
Therapy non-responder 135.32 127.69 30 71 157277 110431921

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065087 Acetylcholine Release Inhibitors
FDA PE N0000175731 Neuromuscular Blockade
FDA MoA N0000175770 Acetylcholine Release Inhibitors
FDA EPC N0000175771 Acetylcholine Release Inhibitor
FDA EPC N0000193962 Neuromuscular Blocker
CHEBI has role CHEBI:176497 geroprotector

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Improvement in the appearance of moderate to severe glabellar lines indication 14667004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Synaptosomal-associated protein 25 Cytosolic other BLOCKER UNKNOWN DRUG LABEL

External reference:

IDSource
1800016-51-6 SECONDARY_CAS_RN
CHEMBL3707322 ChEMBL_ID
C000731258 MESH_SUPPLEMENTAL_RECORD_UI
DB16820 DRUGBANK_ID
C5418435 UMLSCUI
CHEBI:755798 CHEBI
359026 MMSL
41756 MMSL
d10078 MMSL
019552 NDDF
W5O50S8A59 UNII
2689280 RXNORM
1677821000168109 SNOMEDCT_US
D10949 KEGG_DRUG

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LETYBO HUMAN PRESCRIPTION DRUG LABEL 1 81165-050 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 U INTRAMUSCULAR BLA 27 sections
LETYBO HUMAN PRESCRIPTION DRUG LABEL 1 81165-100 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 U INTRAMUSCULAR BLA 27 sections